Literature DB >> 28886266

Metastasis of esophageal small cell carcinoma to the appendix: A case report and literature review.

Qianrong Wang1,2, Tao Zhou2, Hongfu Sun2, Baosheng Li2.   

Abstract

Primary small cell carcinoma (SCC) of the esophagus is characterized by high malignancy with a tendency to metastasize early through lymph and blood circulation. Metastasis of esophageal SCC frequently occurs to distant organs such as liver and lung. However, few cases of appendiceal metastasis have been reported. This paper first presents a pathologically confirmed case with metastasis of esophageal SCC to the appendix. This particular case highlights the importance of pathological diagnosis and provides new evidence of appendiceal metastasis from esophageal SCC.

Entities:  

Keywords:  appendiceal tumor; esophageal small cell carcinoma; metastasis

Mesh:

Year:  2017        PMID: 28886266      PMCID: PMC5663406          DOI: 10.1080/15384047.2017.1360447

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


Introduction

In 1952, Mckeown first reported 2 cases of esophageal small cell carcinoma (SCC). According to recent literature, SCC accounts for 2.4%-2.8% of esophageal tumors,, which usually occurs in the lower and the middle thirds of the esophagus., Distant metastasis has mostly already occurred when the patients are diagnosed, and the 5-year survival rate of esophageal SCC is merely about 4.8%. Therefore, earlier discovery and accurate assessment are extremely important for clinical diagnosis. Here, we report a rare case of esophageal SCC with metastasis to the appendix to provide new reference for diagnosis and treatment of this kind of tumor. To the best of our knowledge, this is the first report of metastasis of esophageal SCC to the appendix. Immunohistochemical staining of lymph node metastases from esophageal SCC demonstrated strong positivity of synaptophysin (Syn) and CD56, while cells of metastatic SCC in appendix expressed Syn and panCK.

Case report

A 57-year-old gentleman was admitted to hospital in April 2016 because of increasing dysphagia and retrosternal pain of one month. He was a former alcohol drinker with a history of smoking cigarettes and severe heart dysfunction. On physical examination an enlarged supraclavicular lymph node was palpable. Computed tomography (CT) scan confirmed a tumor of the lower third of esophagus with enlarged mediastinal and supraclavicular lymph nodes. There was no abnormality in the chest, abdominal space, bone and brain. Gastroscopy demonstrated a submucous protruded lesion of esophagus with a redness of mucosa, arising at 30 cm from the incisors and extending to 35 cm. No biopsy had been taken through gastroscope in consideration of the risk of narcosis for the patient with cardiac insufficiency and fast heart rate. The pathological examination of biopsy of the supraclavicular lymph node demonstrated SCC (Fig. 1A and Fig. 1B). Immunohistochemical staining was analyzed as follows: the staining index for Ki-67: 40% (Fig. 1C), the cells expressing Syn (Fig. 1D) and CD56 (Fig. 1E).
Figure 1.

Pathological images from esophageal SCC. A. Hematoxylin-eosin stain (× 100). B. Hematoxylin-eosin stain (× 200). C.D.E. Immunohistochemical staining in esophageal SCC (× 200). Ki-67: 40%, Syn (+), CD56 (+).

Pathological images from esophageal SCC. A. Hematoxylin-eosin stain (× 100). B. Hematoxylin-eosin stain (× 200). C.D.E. Immunohistochemical staining in esophageal SCC (× 200). Ki-67: 40%, Syn (+), CD56 (+). The patient was treated with a total of 5 cycles of chemotherapy consisting of cisplatin and etoposide and sequential radiotherapy (56Gy/28fractions). The planning target volume included gross tumor volume and draining lymph nodes. After treatment the clinical symptoms were improved significantly and the supraclavicular lymph node could not be palpated. A repeat esophageal barium meal examination in September 2016 indicated that the esophageal lesions disappeared. However, an additional CT scan revealed some residual tumor of esophagus complicated with pneumonia. There was no evidence for extrathoracic extension of the tumor. In December 2016, the patient was readmitted to hospital reporting right lower quadrant pain 3 months after treatment. Physical examination showed tenderness in the right lower abdominal region and no rebound pain. The abdominal pain had resolved completely after injection of bucinnazine in the emergency department. No fever and vomiting were observed. The laboratory values revealed a leukocyte count of 8.66 × 109/L with 84.4% neutrophils, 8.9% lymphocytes, and 5.4% monocytes. C reactive protein level was 141.3mg/L. An abdominal ultrasound indicated a swollen appendix with a large well-defined hypoechoic mass lesion. The CT scan of the chest, abdomen and pelvis showed pulmonary inflammation, hepatic and mesentery lymph node metastases. In particular, the appendix was significantly swollen with the size of 7.2 cm × 2.7 cm (Fig. 2). To find out the nature of the swelling appendix, the electronic colonoscopy was performed and found that the appendix hyperaemia erosion. The pathological report of the biopsy described the presence of metastatic SCC in appendix (Fig. 3A and Fig. 3B). Using immunohistochemical analyses, the staining index for Ki-67 was 80% (Fig. 3C). The cells expressed Syn (Fig. 3D) and panCK (Fig. 3E).
Figure 2.

CT scan of abdomen demonstrating a swollen appendix with an unclear border, uneven density, and heterogeneous enhancement is visible (arrow).

Figure 3.

Pathological results from SCC of appendix. A. Hematoxylin-eosin stain (× 100). B. Hematoxylin-eosin stain (× 200). C.D.E. Immunohistochemical staining in SCC of appendix. Ki-67: 80% (× 100), Syn (+) (× 200), panCK (+) (× 200).

CT scan of abdomen demonstrating a swollen appendix with an unclear border, uneven density, and heterogeneous enhancement is visible (arrow). Pathological results from SCC of appendix. A. Hematoxylin-eosin stain (× 100). B. Hematoxylin-eosin stain (× 200). C.D.E. Immunohistochemical staining in SCC of appendix. Ki-67: 80% (× 100), Syn (+) (× 200), panCK (+) (× 200). The patient was given symptomatic relief and supportive treatment. Unfortunately, he refused to accept further work-up and anti-tumor therapy and left hospital. The patient died of heart failure and liver failure caused of extensive liver metastases in March 2017. The overall survival time was 11 months from initial diagnosis.

Discussion

The SCC is generally found in the bronchial tubes. Primary SCC of the esophagus is thought to be the most common type among extrapulmonary SCC. Like small cell lung cancer, esophageal SCC is characterized by high malignancy with a tendency to metastasize early through lymph and blood circulation associated with a poor prognosis. Metastases of esophageal SCC have mostly already occurred when the patients are diagnosed, and the 5-year survival rate is about 4.8%. The clinical and imaging features of esophageal SCC are lack of specificity. As a result, the correct diagnosis of esophageal SCC mainly depends on histological examination. The esophageal cancer may be incurable when the patient has symptom of dysphagia. The causes of death in patients are closely associated with local recurrence and distant metastasis. The clinical feature of metastatic carcinoma is various, and it is important for clinicians to detect the metastatic tumor earlier. There is evidence indicating esophageal SCC may metastasize to the liver, lung and draining lymph nodes frequently. Mandard et al reported that the lymph node metastases were present in 91% of the esophageal SCC cases by autopsy. 61% of these cases revealed pulmonary metastases and 43% had hepatic metastases. Additionally, metastases in the kidneys, pancreas, adrenal gland, bone, spleen, pleura and multiple metastatic skin nodules have been reported in published literature. Patients usually had extensive dissemination at death. However, it is seldom reported the appendiceal tumor caused by esophageal SCC. The chemotherapy associated with local treatment (radiotherapy or surgery) could be used as standard therapy for SCC of the esophagus. Casas et al concluded that multimodality therapy such as chemotherapy combined with radiotherapy might improve resectability and overall outcome. The appendix is attached to the large intestine. According to reported cases, primary carcinoma of the appendix is a rare malignancy of the gastrointestinal tract, which mostly consists of carcinoid tumor, adenocarcinoma, and mucinous adenocarcinoma., O'Kane et al first presented a case of SCC arising from appendix. CT showed an appendiceal lesion and multiple liver metastases. Histopathological analysis confirmed a primary SCC of the appendix. For the appendiceal tumor, the most common presentation is acute appendicitis. Involvement of the appendix by secondary tumors is few. What's more, it is rare for SCC to metastasis to the appendix. The patient in our case appeared lower quadrant abdominal pain 3 months after sequential chemoradiotherapy. On physical examination he had tenderness in the right lower abdomen without rebound pain and there were no other typical symptoms of appendicitis. Laboratory data were normal except for elevated neutrophil cell count and C reactive protein level, which the attending doctor attributed to the pneumonia. The ultrasound and CT could not confirm the nature of enlarged appendix (inflammation or tumor). Generally speaking, the metastatic appendiceal carcinoma was rare, but it could not be ruled out. The pathological examination of biopsy by colonoscopy led to the diagnosis of appendiceal SCC eventually. In consideration of the poor heart function of the patient, local radiotherapy for appendix was recommended. Chemotherapy could be given if the heart function improved well. The risks of radiation therapy included appendicular perforation and intestinal obstruction. Unfortunately, the patient rejected further anti-tumor therapy and left hospital because of the risks and costs of treatments. Therefore, no therapeutic effects were reported yet. When patients with SCC show symptoms of right lower abdominal pain or acute appendicitis, the clinicians may take the appendiceal tumor into consideration though it is rare clinically. This paper first presents a case with a diagnosis of metastasis of esophageal SCC to the appendix confirmed by pathology of appendix biopsy. Through consulting literature, there are 2 case reports presenting the metastasis from small cell lung cancer to appendix, producing acute appendicitis., Both of the patients had surgery and found gangrenous appendicitis with perforation induced by metastatic SCC of the appendix. The 2 patients were given a new course of chemotherapy. One of them died of acute pneumonia with respiratory function failure. Tumor reduction appeared in the other patient, but there was still an active disease in the abdomen.

Conclusion

To the best of our knowledge, this is the first report of metastasis of esophageal SCC to the appendix in current publications. Primary SCC of the esophagus with high malignancy is likely to metastasize early. It should be noted that whether cancer spreads to uncommon organs. Further examination should be performed in time to avoid diagnostic errors and delayed treatment. This particular case has added to the knowledge of esophageal SCC and highlights the importance of the pathological examination for comprehensive assessment of patient's condition.
  22 in total

1.  Primary appendiceal carcinoma--epidemiology, surgery and survival: results of a German multi-center study.

Authors:  F Benedix; A Reimer; I Gastinger; P Mroczkowski; H Lippert; R Kube
Journal:  Eur J Surg Oncol       Date:  2010-06-18       Impact factor: 4.424

2.  Primary oat cell carcinoma of the oesophagus.

Authors:  S Sabanathan; G P Graham; F D Salama
Journal:  Thorax       Date:  1986-04       Impact factor: 9.139

Review 3.  Metastasis-induced acute appendicitis in small cell bronchogenic carcinoma.

Authors:  L C Pang
Journal:  South Med J       Date:  1988-11       Impact factor: 0.954

Review 4.  Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis.

Authors:  F Casas; F Ferrer; B Farrús; J Casals; A Biete
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

5.  Oat cell carcinoma of esophagus: a report of six British patients with a review of the literature.

Authors:  M A Doherty; M McIntyre; S J Arnott
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-01       Impact factor: 7.038

Review 6.  Extrapulmonary oat cell carcinoma.

Authors:  N B Ibrahim; J C Briggs; C M Corbishley
Journal:  Cancer       Date:  1984-10-15       Impact factor: 6.860

7.  Long-term survival associated with metastatic small cell carcinoma of the esophagus treated by chemotherapy, autologous bone marrow transplantation, and adjuvant radiation therapy.

Authors:  M McCullen; S K Vyas; P J Winwood; C A Loehry; D M Parham; T Hamblin
Journal:  Cancer       Date:  1994-01-01       Impact factor: 6.860

8.  Oat cell carcinomas of the oesophagus: a clinico-pathological study of 23 cases.

Authors:  J C Briggs; N B Ibrahim
Journal:  Histopathology       Date:  1983-03       Impact factor: 5.087

Review 9.  Neoplastic lesions of the appendix.

Authors:  G T Deans; R A Spence
Journal:  Br J Surg       Date:  1995-03       Impact factor: 6.939

10.  Primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical features of 21 cases.

Authors:  Jing-Ping Yun; Mei-Fang Zhang; Jin-Hui Hou; Qiu-Hong Tian; Jia Fu; Xiao-Man Liang; Qiu-Liang Wu; Tie-Hua Rong
Journal:  BMC Cancer       Date:  2007-03-03       Impact factor: 4.430

View more
  2 in total

1.  Rare, Unusual Causality of Acute Appendicitis.

Authors:  Katleen K Janssens; Dorien Mannens; Sabine Declercq; Menno Maes; Steven M Van Outryve
Journal:  J Gastrointest Cancer       Date:  2021-06

2.  Rapidly Extensive Recurrence of Esophageal Neuroendocrine Carcinoma After Complete Pathologic Response to Definitive Chemoradiation.

Authors:  Maxwell M Wang; Simi K Singh
Journal:  ACG Case Rep J       Date:  2022-01-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.